Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Note: In light of President Donald Trump's executive order that threatens to deport foreign pro-Palestinian student protesters — including students with visas — we have blurred all faces in the images ...

Comments: Keytruda sales were $7.8 billion in the quarter, up 19%, driven by continued global demand from metastatic indications, including increased uptake in bladder and endometrial cancers, as well ...

Independent research institute BioMed X has completed its oncology research project in partnership with Merck, the data from which has been acquired by Merck for further development, potentially ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

That R&D takes place not only at big pharma companies—household names such as Pfizer and Merck—but also at smaller, less well-known but no less heroic biosciences startups, such as Vivek ...

Merck & Co’s – known as MSD outside the US and Canada – adult-specific 21-valent pneumococcal conjugate vaccine has been recommended for approval by the European Medicines Agency’s human medicines ...

Merck’s recent earnings call revealed that although the company generated worldwide sales of $64.2 billion—a 7% increase over 2023—the company will be temporarily suspending Gardasil shipments to ...

Jeffrey Sonnenfeld discusses a prolonged stretch of share underperformance for both Pfizer and Merck even with paradoxically good revenues in FORTUNE ...

Estimated Discount To Fair Value: 45% Pharma Mar is trading at €91.05, significantly below its estimated fair value of €165.58, highlighting its undervaluation based on cash flows. Despite a ...